KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 62 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,054,359 | +23.4% | 60,700 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $854,656 | +18.4% | 60,700 | -9.5% | 0.00% | – |
Q1 2023 | $721,996 | -35.7% | 67,100 | -10.4% | 0.00% | -100.0% |
Q4 2022 | $1,122,002 | +20.9% | 74,900 | +3.6% | 0.00% | 0.0% |
Q3 2022 | $928,000 | +32.4% | 72,300 | 0.0% | 0.00% | – |
Q2 2022 | $701,000 | +17.4% | 72,300 | +20.3% | 0.00% | – |
Q1 2022 | $597,000 | -3.9% | 60,100 | +13.8% | 0.00% | – |
Q4 2021 | $621,000 | +3.3% | 52,800 | 0.0% | 0.00% | – |
Q3 2021 | $601,000 | -18.3% | 52,800 | 0.0% | 0.00% | – |
Q2 2021 | $736,000 | -26.6% | 52,800 | -2.6% | 0.00% | -100.0% |
Q1 2021 | $1,003,000 | +8.1% | 54,200 | +3.2% | 0.00% | 0.0% |
Q4 2020 | $928,000 | +15.4% | 52,500 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $804,000 | -18.3% | 52,500 | +36.0% | 0.00% | 0.0% |
Q2 2020 | $984,000 | +492.8% | 38,600 | +97.9% | 0.00% | – |
Q3 2019 | $166,000 | -37.1% | 19,500 | 0.0% | 0.00% | – |
Q2 2019 | $264,000 | – | 19,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |